Breckenridge Pharmaceutical receives FDA approval for anti-cancer drug
Category: #health  | By Nikita Chaurasia  | Date: 2021-06-15 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Breckenridge Pharmaceutical receives FDA approval for anti-cancer drug

According to reliable sources, Natco Pharma’s marketing partner Breckenridge Pharmaceutical Inc. has obtained approval from U.S. Food and Drug Administration (USFDA), for its anti-cancer drug Carfilzomib Vials.

For the record, Carfilzomib Vials is essentially a generic version of the anti-cancer drug Kyprolis. While 10 mg and 60 mg doses of the product have received final approval from the FDA, the 30 mg doses of the product are yet to be approved.

Kyprolis is extensively used in treating multiple myeloma among people who have already received more than one treatment. It was first developed by Onyx Pharmaceuticals.

Natco Pharma and Breckenridge Pharmaceutical had reached a settlement agreement with the product of Onyx Pharmaceuticals back in 2019.

Through the settlement, the two companies have been granted an authorizing license to introduce their generic carfilzomib products. The launch is likely to be in 2027 or earlier based on the situation.

The Hyderabad-based Natco Pharma has teamed up with Breckenridge Pharmaceuticals to commercialize this drug in the U.S, cited sources with relevant information.

Natco Pharma believes that it can acquire 180 days of generic marketing exclusiveness for 10 mg strength as well as 180 days of shared generic marketing exclusivity for 60 mg strength of Carfilzomib Vials during the time of its launch. 

Citing the sales data of the industry, Natco Pharma mentioned that Kyprolis had made annual sales of USD 696 million in the U.S. in 2020 alone, from which, approximately USD 63 million were accumulated just from the sales of 10 mg doses.

About Natco Pharma

Based in Hyderabad, Natco Pharma is a pharmaceutical company that is involved in making final dosage formulations as well as APIs. It is known to be a leading provider of premium oncology medications in India and one of the top producers of hepatitis C drugs.

Source Credits:

https://www.moneycontrol.com/news/business/natco-pharmas-marketing-partner-gets-usfda-nod-for-anti-cancer-drug-7031411.html

 

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...

Pure Health invests $500M in Ardent to expand the company footprint

Pure Health invests $500M in Ardent to expand the company footprint

By Nikita Chaurasia

Pure Health, an integrated healthcare solutions platform, publicized its plans to procure a minority equity share in Ardent Health Services, one of the leading US-based healthcare companies, with an investment of $500 million. According to credibl...